Cellular uptake of vitamin B (cobalamin, Cbl) is mediated by a cell surface receptor (TCblR/CD320) that binds transcobalamin (TC) saturated with Cbl. TC is secreted by the vascular endothelium, has a relatively short half-life, binds Cbl with high affinity and presents the vitamin to the receptor for cellular uptake. Here we show binding and internalization of the TC-Cbl complex along with its' receptor (TCblR) in several human cell lines. The expression of TCblR is linked to the cell cycle with highest expression in actively proliferating cells. Upon binding TC-Cbl, the receptors appear to segregate on the plasma membrane and are internalized over the course of 30-60 min. Subsequently, the receptors appear to be destroyed along with the TC, which results in the release of free Cbl in the lysosome. The appearance of TCblR on the cell surface is limited to newly synthesized protein without contribution from recycling of the receptor. Therefore, Cbl uptake into cells is fully dependent on the expression of newly synthesized TCblR that is up-regulated in actively proliferating cells. The cell cycle-associated up-regulation of TCblR in cancers provides a route for targeted drug delivery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.yexcr.2020.112256 | DOI Listing |
AAPS PharmSciTech
January 2025
College of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, 330004, China.
Valsartan (VST) is an angiotensin II receptor antagonist with low oral bioavailability. The present study developed a solid self-nanoemulsifying drug delivery system (S-SNEDDS) to enhance the oral absorption and bioavailability of VST. VST-loaded liquid SNEDDS (VST@L-SNEDDS) was prepared by investigating the solubility of VST and constructing the pseudo-ternary phase diagrams.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Bio-System Pharmacology, Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
L-type amino acid transporter 1 (LAT1, SLC7A5), overexpressed in various cancers, mediates the uptake of essential amino acids crucial for tumor growth. It has emerged as a promising target for cancer therapy. Nanvuranlat (JPH203/KYT-0353), a LAT1 inhibitor, has shown antitumor activity in preclinical studies and efficacy in biliary tract cancer during clinical trials.
View Article and Find Full Text PDFJ Nucl Med
January 2025
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China
Fibroblast activation protein (FAP) has been considered a promising target for tumor imaging and therapy. This study designed a novel peptide, FAP-HXN, specifically targeting FAP and exhibiting significant potential as a radionuclide-labeled theranostic agent. Preclinical studies were conducted to evaluate the potency, selectivity, and efficacy of FAP-HXN.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
Unimore Microbial Culture Collection Laboratory, Department of Life Sciences, University of Modena and Reggio Emilia, 42124 Reggio Emilia, Italy. Electronic address:
Inspired by natural microbial cooperation, a co-culture approach was used to synthesize bacterial nanocellulose (BNC)-based nanocomposites for potential wound healing applications. By co-culturing either Komagataeibacter xylinus (K1G4) or the never tested strain K. rhaeticus (K2G46) with the hyaluronic acid (HA)-producer Lacticaseibacillus casei UMCC 2535, two BNC-HA nanocomposites were obtained (C1-K1 and C2-K2).
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
Department of Chemistry, Faculty of Science, Tarbiat Modares University, Tehran, Iran.
This study explores the development of a sustainable drug delivery system using cellulose nanoparticles (CNPs) derived from potato pulp for the controlled release of phosphoaminopyrazine (PAP), a promising anticancer agent. CNPs were synthesized via nanoprecipitation, and PAP was loaded through in-situ nanoprecipitation, achieving a high loading efficiency of 79.2 %.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!